The aim of this study was to evaluate the efficacy and safety of erlotinib, an epidermal growth
factor receptor tyrosine kinase inhibitor, in Japanese patients with relapsed or recurrent …

To evaluate the efficacy and safety of erlotinib for non-small cell lung cancer (NSCLC), we
performed a population-based observational study. The study involved 307 patients treated …

Introduction The aim of this study was to evaluate the efficacy and safety of Erlotinib in
Japanese patients with previously treated non-small cell lung cancer (NSCLC). Available …

Purpose: Erlotinib has proven activity in pretreated patients with advanced non–small cell
lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC …

Objective This study is to analyze the data of Chinese subpopulation in the Tarceva Lung
Cancer Survival Treatment Study (TRUST-China) which was a global Phase IV study …

Introduction: Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor that
significantly increases survival for patients with previously treated advanced non-small cell …

Background Erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) is an oral, epidermal
growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good …

Erlotinib is a highly potent inhibitor of epidermal growth factor receptor tyrosine-kinase
activity that significantly prolongs overall survival in patients with non-small-cell lung cancer …

Aims: The efficacy of erlotinib (Tarceva, Roche Products, Dee Why, Australia) has been
demonstrated in patients with advanced non‐small‐cell lung cancer (NSCLC). Tarceva lung …

Introduction: Interstitial lung disease (ILD) is an adverse drug reaction (ADR) of concern in
Japanese patients with non–small-cell lung cancer (NSCLC) receiving erlotinib. To …